about
Deferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing transfusional iron overload in people with sickle cell diseaseSickle cell disease in childrenIron chelation therapy in myelodysplastic syndromes.Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Reversible retinopathy associated with oral deferasirox therapyThe global burden of iron overload.Deferasirox for managing iron overload in people with thalassaemia.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Perforated duodenal ulcer: a rare complication of deferasirox in children.Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).Chelation of thallium by combining deferasirox and desferrioxamine in rats.Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model.
P2860
Q24194549-0A5F634E-2200-4FEE-AFD6-271B38A0D4ABQ24203718-BB2FE211-52E8-4203-BD97-7228722406C7Q24236463-D5E29C11-F846-43FD-AE61-9415970642FAQ26864582-58F38D71-BAFD-4503-ABF4-D1E904FC9675Q34002840-933126C5-D950-4103-9A35-16F44DA3AF55Q35088183-E1DB9E60-4338-485F-8FC5-2ECD31AAE488Q36681744-CFF9A888-D437-4ED3-B50F-FFD96A3E5C4DQ37076801-F6BEA03B-2B77-4B70-B880-97EA98E8BAE6Q37356785-F3D4232B-2599-4E80-94D5-AE50248EA935Q38624033-255E0AF8-ED51-4E16-B2C3-E6C7FA7CCDF9Q39269756-9B14C201-3405-443B-BCE3-F1EDD08EF725Q41483158-3F5F6B04-7642-4661-BBC6-2FEFC6A44BDBQ43413539-06C9EEF5-B303-455C-9DA9-4700FFDFF333Q43750571-ED949182-D556-4368-BC77-B7A68A3525ABQ43942281-A2A81911-50A1-4FF4-95B1-AFC6A436DB73Q44476390-AAD1CFD0-5D58-421E-A765-72FE30F49738Q47581898-06AA5ADA-3DB1-4259-A8DF-F71593C988D3Q50482668-970F4C55-9DFC-46F5-8C97-FB20CD88273C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term efficacy and safety of deferasirox.
@en
Long-term efficacy and safety of deferasirox.
@nl
type
label
Long-term efficacy and safety of deferasirox.
@en
Long-term efficacy and safety of deferasirox.
@nl
prefLabel
Long-term efficacy and safety of deferasirox.
@en
Long-term efficacy and safety of deferasirox.
@nl
P1433
P1476
Long-term efficacy and safety of deferasirox
@en
P2093
Maria Domenica Cappellini
P304
P356
10.1016/S0268-960X(08)70007-9
P478
22 Suppl 2
P577
2008-12-01T00:00:00Z